Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Trading Symbol Entity Common Stock, Shares Outstanding Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Disclosure Text Block [Abstract] Fair Value, Measurement Inputs, Disclosure [Text Block] License Agreements [Abstract] License Agreements [Text Block] The entire disclosure for license agreements. Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Disclosure Text Block Supplement [Abstract] Financing Receivables [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Statement of Financial Position [Abstract] Statement [Table] Unrecognised Tax Benefits Disclosure [Table] Class of Stock [Domain] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of year Cash at end of year Restricted Cash and Cash Equivalents, Current Restricted cash Other Assets, Current Other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property and equipment, at cost, net of accumulated depreciation of $77 and $51 Property, Plant and Equipment, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total In-process research and development acquired In-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill (in Dollars) Intangible Assets, Net (Excluding Goodwill), Total Intangible assets, net Balance Balance Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Due to Related Parties, Current Due to related parties Derivative Liability, Current Derivative financial instruments, warrants Derivative liability related to Hercules Warrants Notes and Loans Payable, Current, Total Notes and loans payable, current portion, net of debt discount Notes and loans payable, current portion Accounts Payable, Other Grants payable Notes And Loans Payable Net Of Current Portion and Debt Discount Notes and loans payable, net of current portion Notes and loans payable, net of current portion and debt discount. Capital Lease Obligations, Noncurrent Obligations under capital lease, net of current portion and debt discount Derivative Liability, Noncurrent Series D preferred stock derivative liability Series D Preferred Stock Derivative Liability Deferred Tax Liabilities, Net, Noncurrent Deferred tax liability Deferred Tax Liabilities, Net, Noncurrent (in Dollars) Liabilities, Total Total liabilities Preferred Stock, Value, Issued Series C Preferred Stock, par value $0.0001; 15,000 shares authorized, 2,832 shares issued and 0 shares outstanding as of December 31, 2015, and 2,832 shares issued and outstanding, as of December 31, 2014 Balance Balance Common Stock, Value, Issued Common stock, $0.0001 par value; authorized 225,000,000 shares; 28,907,278 and 23,975,358 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Temporary Equity, Carrying Amount, Attributable to Parent Series D Preferred Stock, net of discount, par value $0.0001, 12,000 shares authorized, 1,263 shares issued and 963 shares outstanding as of December 31, 2015 and 0 shares issued and outstanding as of December 31, 2014 Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Presentation And Principles Of Consolidation [Policy Text Block] Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles. Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] Segment Reporting, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Inputs, Assets, Quantitative Information [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Series C Preferred Stock [Member] Series C Preferred Stock [Member] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, accumulated depreciation (in Dollars) Less accumulated depreciation Less accumulated depreciation Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Balance (in Shares) Balance (in shares) Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Schedule of Debt [Table Text Block] Schedule of Debt [Table Text Block] Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of Share-based Compensation, Activity [Table Text Block] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Significant Accounting Policies [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Project [Axis] Project [Domain] Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Equity Components [Axis] Fair Value Inputs, Assets, Quantitative Information [Table] Equity Component [Domain] Range [Axis] Range [Domain] Deriavtive Inception Date [Axis] Income Statement [Abstract] Revenues Revenue Research and Development Expense Research and development Selling, General and Administrative Expense General and administrative Costs and Expenses Total costs and expenses Costs and Expenses [Abstract] Costs and expenses: Operating Income (Loss) Loss from operations Interest Expense Interest expense Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Derivative liability instrument expense Warrant amendment expense Warrant amendment expense Warrant amendment expense The aggregate amount of income or expense on warrant amendment expense Gains (Losses) on Extinguishment of Debt Loss on extinguishment of debt Nonoperating Income (Expense) [Abstract] Non-operating expense: Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Net loss before income taxes Net Income (Loss) Attributable to Parent Net loss Net loss Loss for the period Deemed Dividend Deemed dividend Deemed dividend A company with a deemed dividend pays the taxes on the value of the dividend and the shareholders increase the cost basis of their shares. This is of benefit to the shareholders as it reduces the tax obligation upon the sale of the shares. Shareholders should receive a Form 2439 from their broker when a deemed dividend is issued. Dividends, Preferred Stock, Stock Series C Preferred Stock dividend Dividend Series C Preferred Stock Accrued dividends on Series C Preferred Stock Net Income (Loss) Available to Common Stockholders, Basic Loss attributable to common stockholders Net loss attributable to common stockholders Net income (loss) attributable to shares of common stock Schedule Of License Agreements [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Counterparty Name [Axis] Counterparty Name [Domain] Dalhousie University [Member] iCo [Member] Bertilimumab iCo [Member] Yissum [Member] NanomAbs Yissum [Member] Kadouche [Member] Human Antibodies Kadouche [Member] Lonza [Member] Shire BioChem [Member] Ordinary Shares [Member] Nature of Expense [Axis] Interim Period, Costs Not Allocable [Domain] Cash Payment [Member] Annual Payments - License Cost [Member] Annual Payments, Sublicense [Member] Cell Line Payments [Member] Asset Class [Axis] Asset Class [Domain] Exclusive License Rights [Member] Report Date [Axis] Financial Statement Filing Date [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Scenario [Axis] Scenario, Unspecified [Domain] Patent Coverage Available [Member] Data Protection Available [Member] Achievement of Milestoe Marks [Member] License Costs Stock Issued During Period, Shares, Other Series C preferred stock exchange (in shares) Issuance of ordinary shares in connection with consulting agreement (in shares) Stock Issued During Period, Value, Other Series C preferred stock exchange Issuance of ordinary shares in connection with consulting agreement Shares Issued, Price Per Share Class of Warrant or Right Issued Class of Warrant or Right, Issued Convertible Debt, Fair Value Disclosures Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants outstanding and exercisable (in Dollars per item) Warrants outstanding and exercisable (in Dollars per item) Percent of Companies Issued and Outstanding Share Capital Percent of Companies Issued and Outstanding Share Capital. Dilution Rate Dilution Rate Pre Money Valuation Minimum Pre-Money Valuation Minimum Derivative Liability Derivative Liability Expense Fair value adjustment at reclassification, included in statement of operations Fair value adjustment at reclassification, included in statement of operations Derivative liability expense Milestone Payments Milestone Payments Licenses Revenue Royalty Rate Percent of Net Sales Royalty Rate, Percent of Net Sales Royalty Rate, Percent of Net Sales Royalty Rate Net Selling Price Of The Product Royalty Rate Net Selling Price Of The Product